MacroGenics Inc at American Society of Clinical Oncology Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the MacroGenics ASCO 2019 Conference Call. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to introduce your host for today's conference, Anna Krassowska, Investor Relations. You may begin.
Thank you, operator. Good afternoon, and welcome to the MacroGenics conference call to review the margetuximab Phase III SOPHIA study presentation at the American Society of Clinical Oncology or ASCO annual meeting and discuss ongoing and future clinical development plans for the program.
The presentation that accompanies this conference call is available under the Investors tab on our website at www.macrogenics.com. You can listen to this conference call live via webcast on the website where it will be archived for 30 days beginning approximately 2 hours after the call is completed.
Before we begin, I would like to alert
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |